Drug Trial Radar · NCT00651612
Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients
Last checked: Nov 19, 2026Latest source record: Apr 3, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
604
Actual
Start
Nov 2005
Primary completion
Jan 2007
Study completion Jan 2007
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Apr 3, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the safety of brimonidine/timolol fixed combination in glaucoma or ocular hypertension patients
Conditions
- Glaucoma
- Ocular Hypertension
Interventions
Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic SolutionDrug
Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)
Concurrent brimonidine 0.2% and 0.5% timololDrug
Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: Day 10
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Newport Beach, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.